Physician profile
Sharmila Devidoss
NPI 1124169396
$1,147.71
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.59 · 2020: $47.40 · 2021: $291 · 2022: $731.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $256.69 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $199.09 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $151.96 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $150.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.43 | 2020-2022 | |
| Amgen INC. | $74.92 | 2022 | |
| Horizon Therapeutics Plc | $68.97 | 2019-2022 | |
| Vifor Pharma, INC. | $40.95 | 2022 | |
| Ani Pharmaceuticals, INC. | $29.47 | 2022 | |
| Akebia Therapeutics INC | $27.48 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $17.28 | 2019 | |
| Calliditas Therapeutics US INC. | $14.88 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharmila Devidoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.